AI assistant
AstraZeneca PLC — Director's Dealing 2017
May 24, 2017
5229_dirs_2017-05-24_4f9cb013-ae0e-46ae-af94-27de51a5866e.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1090G
AstraZeneca PLC
24 May 2017
24 May 2017 15:00 BST
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 23 May 2017, it was notified by Mark Mallon, a Person Discharging Managerial Responsibilities of the Company, that, on 23 May 2017, Mr Mallon sold 20,000 American Depositary Shares (ADSs). Two ADSs are equivalent to one ordinary share of $0.25 in the Company.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mark Mallon
2
Reason for the notification
a)
Position/status
Person Discharging Managerial Responsibilities
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
AstraZeneca PLC
b)
LEI
PY6ZZQWO2IZFZC3IOL08
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
b)
Nature of the transaction
Sale of AstraZeneca PLC American Depositary Shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| US$ 33.900214 | 20,000 |
d)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
e)
Date of the transaction
23 May 2017
f)
Place of the transaction
NYSE
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Enquiries | ||
| Esra Erkal-Paler | UK/Global | +44 203 749 5638 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Mitchell Chan | Oncology | +1 240 477 3771 |
| Lindsey Trickett | Cardiovascular & Metabolic Diseases | +1 240 543 7970 |
| Nick Stone | Respiratory | +44 203 749 5716 |
| Christer Gruvris | Autoimmunity, Neuroscience & Infection | +44 203 749 5711 |
| US toll free | +1 866 381 7277 |
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUSARRBVAVUAR